Uploaded August 2024 | Updated November 2026, 1 day ago
Ashley was diagnosed with acute disseminated encephalomyelitis (ADEM) in 2007 when she was in college. Her journey has been marked by resilience and the relentless pursuit of better health, demonstrating the powerful impact of determination and support within the SRNA community. Ashley's story is a testament to the power of community and the difference it can make in the lives of those impacted by rare neuroimmune disorders.
Ashley was diagnosed with acute disseminated encephalomyelitis (ADEM) in 2007 when she was in college. Her journey has been marked by resilience and the relentless pursuit of better health, demonstrating the powerful impact of determination and support within the SRNA community. Ashley's story is a testament to the power of community and the difference it can make in the lives of those impacted by rare neuroimmune disorders.
![2024 RNDS | Cannabis Use in Rare Neuroimmune Disorders
At the 2024 RNDS, Melanie Delgado and Dr. Anastasia Vishnevetsky discussed their cross-sectional survey study on cannabis use among individuals with CNS neuroinflammatory diseases, emphasizing the lack of existing literature on the subject and detailing the studys objectives and methodology [00:01:05]. The study surveyed 267 respondents, analyzing demographics, reasons for cannabis use, targeted symptoms, frequency and methods of use, effectiveness, and side effects [00:02:27]. Findings revealed that most respondents used cannabis primarily for sleep disturbances, muscle spasms, pain, and anxiety, with oral consumption being the most common method [00:03:57]. In conclusion, Melanie highlighted the need for more prospective research to guide safe and appropriate cannabis use for patients with these conditions [00:08:34]. Melanie and Dr. Vishnevetsky also answered questions from the audience [00:10:48]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction and Acknowledgements
00:41 Study Motivation and Background
01:40 Methodology and Study Design
02:27 Study Objectives and Participant Demographics
03:57 Cannabis Use Patterns and Effectiveness
06:58 Side Effects and Barriers to Cannabis Use
08:34 Patient-Provider Communication and Conclusions
10:48 Q&A Session 2024 RNDS | Cannabis Use in Rare Neuroimmune Disorders](https://i.ytimg.com/vi/5FRlANElDfs/mqdefault.jpg)
![2024 RNDS | Social Determinants of Health in TM
At the 2024 RNDS, Ka-Ho Wong discussed the project on social determinants of health in myelopathy and transverse myelitis, highlighting its funding by SRNA [00:00:10]. Ka-Ho explained the five categories of social determinants of health as defined by Healthy People 2030 and their relevance to neurology [00:01:05]. Various studies were cited, including ones focusing on neighborhood disadvantage, stress, and socioeconomic status affecting conditions like neuromyelitis optica spectrum disorder (NMOSD) [00:02:30]. Ka-Ho also delved into ongoing and future research projects to better understand the impact of social determinants on neuroimmune disease outcomes [00:05:45]. Finally, Ka-Ho answered questions from the audience [00:11:25]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction and Acknowledgements
00:27 Understanding Social Determinants of Health
01:26 Social Determinants in Neurology
02:18 Research on Rare Neuroimmune Disorders
04:03 Transverse Myelitis Outcome Project
06:32 Survey Studies and Preliminary Results
11:25 Q&A Session 2024 RNDS | Social Determinants of Health in TM](https://i.ytimg.com/vi/5PnUvATDr0I/mqdefault.jpg)
![2024 RNDS | Disability: Adapting to and Embracing Disability
At the 2024 RNDS, Dr. Cyrena Gawuga discussed the differences between the medical and social models of disability and emphasized societys role in accommodating individuals with disabilities [00:00:24]. She shared her personal journey and how it shaped her understanding of disability [00:03:09]. Dr. Gawuga explained the value of inspiration and advocated for broader societal acceptance and support [00:07:36]. The talk concluded with answering questions from the audience, and encouraging individuals to embrace their identity and accomplishments without seeking external validation [00:10:34]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction and Speaker Background
00:24 Understanding the Concept of Disability
01:23 Medical vs. Social Model of Disability
03:09 Personal Journey and Realizations
06:16 Disability Advocacy and Social Change
07:36 Challenging Inspirational Narratives
10:34 Embracing Disability Pride
17:20 Conclusion and Final Thoughts
19:20 Audience Questions 2024 RNDS | Disability: Adapting to and Embracing Disability](https://i.ytimg.com/vi/6GP6E3nSM_Q/mqdefault.jpg)
![2026 RNDS | Closing Remarks
In this closing session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Michael Levy, MD, PhD, of Massachusetts General Hospital, and SRNA Executive Director GG deFiebre closed the three-day symposium [00:00:05]. Dr. Levy led applause for the speakers, the SRNA staff who put the event on, and everyone who stayed to the end [00:00:05]. GG thanked those attending online and in person, and the presenting sponsors Alexion, Amgen, Genentech and UCB, along with Kennedy Krieger and Grapevine [00:01:00]. Attendees used their phones to share one-word takeaways, including empowerment, validation, hope and community [00:01:39]. They also answered how they felt after three days, and Dr. Levy ended with one word of his own: thank you [00:03:05].
Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology and Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine and trained at Johns Hopkins, where he started the Neuromyelitis Optica Clinic and Research Laboratory. In 2019, he moved to Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.
00:00 Welcome and Applause
00:34 Thanks to Everyone Who Stayed
01:00 Thanks from SRNA and Sponsors
01:39 Biggest Takeaway Poll
03:05 How Are You Feeling
04:06 One Word for RNDS
04:35 Final Thanks 2026 RNDS | Closing Remarks](https://i.ytimg.com/vi/6HhK0WJurYc/mqdefault.jpg)
![2024 RNDS | NMOSD and MOGAD Clinical Trials
At the 2024 RNDS, Dr. Michael Levy of Massachusetts General Hospital discussed various therapeutic approaches for MOG antibody disease (MOGAD), transverse myelitis (TM), and neuromyelitis optica spectrum disorder (NMOSD), including acute therapy, preventive therapy, regenerative therapy, and symptomatic trials. Details were provided on specific trials such as the rozanolixizumab trial for MOGAD and the use of satralizumab for NMOSD [00:00:58]. Another focus was on a study investigating the impact of a dairy-free diet on MOG antibody levels [00:01:58]. Dr. Levy also mentioned acute treatment trials and the potential impact of cannabis-based products on improving quality of life for those diagnosed with NMOSD [00:11:16]. He concluded by answering audience questions [00:15:34]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
You can view the presentation slides here:
https://files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Levy.pdf
00:00 Introduction to MOGAD, TM, and NMOSD Trials
00:13 Understanding Acute and Preventive Therapies
00:32 Exploring Regenerative and Symptomatic Therapies
00:58 Current Trials in NMOSD
01:58 MOGAD Trials
02:28 Mechanism of Action: FcRn Blockers
04:19 Trial Design and Enrollment
05:38 Enspryng Trials for MOGAD
07:39 Dairy-Free Diet Study
11:16 Acute Treatment Trials
13:54 Nabiximols for NMOSD Quality of Life
15:28 Audience Questions 2024 RNDS | NMOSD and MOGAD Clinical Trials](https://i.ytimg.com/vi/75Bwop2jNXo/mqdefault.jpg)
![1214. Self Identity and Finding Meaning Following Diagnosis
In this Ask the Expert episode, Krissy Dilger of SRNA spoke with Susan Y. Wegener, LCSW, a licensed clinical social worker, about coping with a chronic diagnosis and its emotional adjustments, referencing Kübler-Ross’ stages of grief [00:03:45]. Susan discussed the importance of self identity transformation post-diagnosis and the need for patience and self-compassion in finding new ways to move forward [00:08:34]. The value of inner strength, setting priorities, and support groups for reducing isolation and fostering compassion was emphasized [00:15:20]. The discussion concluded with a focus on post-traumatic growth, highlighting greater life appreciation and mental flexibility as key coping strategies [00:16:01].
Susan Y. Wegener, LCSW is a licensed clinical social worker who maintains a private psychotherapy practice in Austin, TX. Her clinical practice specializes in work with individuals coping with chronic medical diagnoses. She completed her undergraduate degree, in Psychology, from Skidmore College, Saratoga Springs N.Y., 1993 and her graduate degree, in Social Work from Columbia University, New York City in 1995. In addition to her private practice, she has worked in multiple medical settings throughout her career and helped to empower and support individuals from diagnosis through the adjustment process. She became a Partner in Care for the National Multiple Sclerosis Society in 2017 and is passionate about her work with individuals diagnosed with MS and various other neurological diagnoses. In her free time, she enjoys singing in a local chorus, cooking, swimming, and spending time with her family. Please see the following link to her workbook “Hold on to Hope.”
https://www.amazon.com/Hold-Hope-Overview-Strategies-Chronic/dp/1512218715
00:00 Introduction to the Podcast
00:37 Meet the Expert: Susan Wagner
01:00 Coping with a Chronic Diagnosis
01:47 The Emotional Adjustment Process
05:36 Understanding Self Identity Post-Diagnosis
08:34 Dealing with Denial
10:39 Coping Strategies for Shifting Self Identity
14:08 Finding Meaning and Purpose
14:26 Exploring the Impact of Diagnosis
15:25 Reflecting on Values and Strengths
16:06 Coping Strategies for Finding Meaning
16:29 The Role of Relationships and Support Systems
18:05 Prioritizing Self-Care and Realistic Goals
20:04 Finding Meaning in Suffering
20:15 The Concept of Post-Traumatic Growth
24:52 The Importance of Stillness and Self-Compassion
28:31 Mental Flexibility and Creative Thinking
30:02 Conclusion and Final Thoughts 1214. Self Identity and Finding Meaning Following Diagnosis](https://i.ytimg.com/vi/8-4AgHzzMrA/mqdefault.jpg)
![Community Meets Clinic 304. Dr. Ayşe Altıntaş
The Community Meets Clinic podcast series introduces clinicians and healthcare personnel specializing in rare neuroimmune disorders. In this episode, Krissy Dilger of SRNA spoke with Dr. Ayşe Altıntaş, Professor of Neurology at Koç University School of Medicine in Istanbul, Turkey, which has been designated as a Center of Excellence in Rare Neuroimmune Disorders. Dr. Altıntaş described the unmet needs in rare neuroimmune disorders and noted her role on an international panel developing updated NMOSD diagnostic criteria [00:03:40]. She outlined current research on mechanisms of optic neuritis, pregnancy complications and aquaporin-4 antibodies, and developing accessible biomarkers beyond CSF with a future goal of remote monitoring [00:06:01]. Dr. Altıntaş also explained Koç University’s multidisciplinary demyelinating disease center model, emphasizing coordinated consultations, advanced MRI capabilities, shared decision-making, and the value of specialized centers, while expressing hope due to rapid advances in biomarkers and targeted therapies [00:11:43]. You can view the medical profile of Dr. Ayşe Altıntaş here:
https://www.kuh.ku.edu.tr/doctors/ayse-altintas
Ayşe Altıntaş, MD is a professor of neurology at Koç University School of Medicine in Istanbul, Türkiye. She graduated from Ege University Faculty of Medicine in 1986 and completed her neurology residency there in 1992. She received early training in neuroimmunology as a fellow at Mayo Clinic under Prof. Moses Rodriguez and later continued her research at Mayo Clinic with Prof. Claudia Lucchinetti and Prof. Brian Weinshenker, focusing on the animal model, immunopathology, and imaging correlates of multiple sclerosis.
Prof. Altıntaş served at Istanbul University Cerrahpaşa School of Medicine for 23 years before joining Koç University in 2018, where she established a neuroimmunology laboratory and continues to lead clinical and translational research. Her work focuses on multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD) and MOG antibody-associated diseases (MOGAD), with an emphasis on biomarkers and disease mechanisms. She is actively involved in international organizations, including BioMS-eu, The MOG Project, Siegel Rare Neuroimmune Association (SRNA), MEDEN, the MSBase Scientific Leadership Group, and the Guthy-Jackson Charitable Foundation International Scientific Consortium.
00:00 Welcome and Guest Intro
01:39 Why Neurology
03:40 Choosing Rare Disorders
06:01 Current Research Projects
11:43 Clinic Team and Workflow
15:48 Advanced Imaging and Coordination
17:20 Self Care and Balance
20:20 Advice for New Patients
22:17 Hope for the Future
24:34 Closing Community Meets Clinic 304. Dr. Ayşe Altıntaş](https://i.ytimg.com/vi/8Ih_dfaRGS0/mqdefault.jpg)



